Bank of America’s Dermata Therapeutics DRMA Stock Holding History

Bank of America’s Portfolio DRMA Stock Details DRMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-3,457	Closed	-$8.02K	–	6036
2025 Q4	$8.02K	Buy	3,457 +3,453	+86,325%	+$11.3K	﹤0.01%	6201
2025 Q3	$20	Buy	4 +1	+33%	+$6	﹤0.01%	8162
2025 Q2	$18	Buy	3 +1	+50%	+$8	﹤0.01%	8253
2025 Q1	$23	Hold	2	–	–	﹤0.01%	8107
2024 Q4	$22	Buy	2 +1	+100%	+$13	﹤0.01%	8007
2024 Q3	$16	Buy	+1	New	+$20	﹤0.01%	7998
2024 Q2	–	Hold	0	–	–	–	8109

Other funds holding DRMA

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Welch & Forbes Boston, Massachusetts $8.23B AUM 17.62% 1-Year Est. Return

MCF Advisors Covington, Kentucky $2.28B AUM 14.87% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Bank of America's DRMA Position: Q1 2026 in Review

Bank of America sold out of Dermata Therapeutics (DRMA) in Q1 2026, closing a stake of 3,457 shares — an estimated $8.02K sold.

Bank of America first reported a position in DRMA in Q3 2024 and held it in 6 quarters. The position peaked at $8.02K in Q4 2025. 7 funds tracked by Wall St. Rank hold DRMA as of Q1 2026.

Bank of America reported no remaining Dermata Therapeutics position as of Q1 2026 after selling out during the quarter.
Bank of America sold 3,457 Dermata Therapeutics shares in Q1 2026, an estimated $8.02K.
Bank of America first reported a position in Dermata Therapeutics in Q3 2024 and held it in 6 quarters.
Bank of America's Dermata Therapeutics position peaked at $8.02K in Q4 2025.
7 funds tracked by Wall St. Rank held Dermata Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.